What changed for Stomach Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Stomach Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 26 to 27 (+1)
- Trials recruiting worldwide 567 to 570 (+3)
- Late-stage (Phase 3) trials 58 to 59 (+1)
- Trials on record 3,066 to 3,116 (+50)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Stomach Cancer yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 112 trials tracked for Stomach Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04879368 · results posted 10 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04879368) enrolled 462 people with advanced gastric or other related cancers, split into two groups: 309 people received a combination treatment called "RegoNivo" and 153 received standard of care. The trial was primarily measuring how long participants lived overall (called overall survival), and also tracked a number of secondary measures including how long before the disease got worse, how many people's tumours shrank, and how participants' physical wellbeing and quality of life held up over time. The reported data sho...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04736485 · results posted 14 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04736485) enrolled 67 participants, all of whom were placed in a single experimental treatment group. All 67 participants completed the study with none dropping out. The trial was measuring how well a pre-operative (before surgery) treatment could shrink or eliminate tumour tissue in people with stomach or related cancers, as judged by a pathologist examining tissue removed during surgery. The reported data shows that out of the 67 participants, 20 were recorded as having a pathologic complete response — meaning no remain...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05525286 · results posted 17 November 2025
According to the results reported on ClinicalTrials.gov, this trial tested an experimental drug called SOT102 in people with cancer. The trial had two main parts: Part A tested SOT102 on its own at four increasing dose levels (ranging from 0.032 mg/kg up to 0.214 mg/kg), and Part B tested SOT102 alongside standard-of-care treatment at the lowest dose level. In total, 31 participants were enrolled across these groups — 4 at the lowest monotherapy dose, 11 at the second dose, 9 at the third dose, 3 at the highest dose, and 4 in the combination group. The trial was designed to find the highest do...
-
NCT03797326 · results posted 17 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03797326) enrolled a total of 611 participants across eight groups, each covering a different cancer type: triple negative breast cancer, ovarian cancer, gastric cancer, colorectal cancer (two separate groups — one receiving a combination treatment and one receiving a single treatment), glioblastoma (a type of brain tumour), biliary tract cancer, and pancreatic cancer. The trial was measuring how tumours responded to treatment combinations involving lenvatinib (referred to as "Lenva") and pembrolizumab (referred to as "Pem...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04189445 · results posted 8 October 2025
According to the results reported on ClinicalTrials.gov, this trial investigated a drug called futibatinib in people with certain cancers. Participants were divided into groups — Cohort A (87 people) and Cohort B (28 people). A third group, Cohort C, was listed but had no participants enrolled. The trial was measuring how many participants experienced a meaningful shrinkage of their tumours, how long any such response lasted, and how long participants went without their disease getting worse. The reported data shows that the main outcome measured — the proportion of participants whose tumours...
-
NCT04164979 · results posted 11 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 27 adults with advanced stomach or gastro-oesophageal cancer (a cancer affecting the stomach and the junction where the oesophagus meets the stomach). All 27 participants completed the study. Everyone received a combination of two medicines — cabozantinib and pembrolizumab — and the trial was primarily measuring how many people were still free from their cancer getting worse at the 6-month mark. Several additional outcomes were also tracked, including how many people experienced serious side effects, how many showed a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05011058 · results posted 28 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05011058) enrolled a total of 102 participants across eight different types of lymphoma (a cancer of the lymphatic system). The groups included people with Diffuse Large B-Cell Lymphoma (9 people), Extranodal Natural Killer/T-Cell Lymphoma (11), Peripheral T-Cell Lymphoma receiving combination therapy (38), Peripheral T-Cell Lymphoma receiving a single treatment (10), Hodgkin Lymphoma (8), Post-Transplant Lymphoproliferative Disorders (3), HIV-Associated Lymphomas (3), and other Epstein-Barr virus (EBV)-positive lymphomas...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05104567 · results posted 1 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05104567) enrolled 138 adults in total across seven groups, each made up of people with one of several different advanced gastrointestinal cancers — including oesophageal, stomach, liver, and bowel cancers. Participants had already received prior treatments. Each group received a combination of the investigational drug pegenzileukin with either pembrolizumab or cetuximab (both existing cancer medicines). The main thing the trial was measuring was the **objective response rate (ORR)** — that is, the proportion of participan...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03008278 · results posted 4 June 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two drugs — olaparib and ramucirumab — in people with cancer. The study ran in two parts: a Phase 1 portion to find a safe starting dose, and a Phase 2 portion to look at how many patients' tumours responded to the treatment. A total of 51 people were enrolled across three groups (3 in an early Phase 1 level, 8 in a later Phase 1 level, and 40 in Phase 2). Of those, only a small number completed the study as planned — 3, 6, and 1 respectively — with most participants in Phase 2 not completing the stu...
-
NCT04383938 · results posted 13 May 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two medicines — APR-246 and pembrolizumab — in people with solid tumours (cancers that form lumps or masses). A total of 40 people took part across four groups: a "Safety Lead In" group (6 people), and three "Expansion" groups (8, 5, and 21 people respectively). The trial had two main goals: to track how often participants experienced treatment-related side effects or serious medical events, and to find a recommended dose of APR-246 to use in later research. The reported data shows that, when counti...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05311176 · results posted 11 May 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two drugs — IMU-131 and pembrolizumab — given together to cancer patients. Seven people started the trial and all seven received at least one dose of the study drugs. None of the seven participants were recorded as having completed the trial. The study was measuring how often participants experienced unwanted medical events (called adverse events), including a specific category of immune-related side effects, as well as whether any participants' tumours shrank or disappeared in response to the treatm...
-
NCT04288661 · results posted 27 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04288661) involved 60 people who had undergone a total gastrectomy (surgical removal of the stomach). Participants were split into two groups: 40 people who had a drain (a small tube placed near the surgical join to remove fluid) inserted after their operation, and 20 people who did not have a drain placed. The trial was measuring several immediate post-operative experiences, including pain levels, nausea and vomiting, when feeding and movement began, bowel activity, and how long people stayed in hospital. The reported da...
-
NCT04082364 · results posted 22 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04082364) enrolled a total of 82 participants across five treatment groups. The largest group, called "Part A" or the "chemotherapy-free arm," included 48 participants who received a combination of two drugs — margetuximab and retifanlimab — without chemotherapy. The remaining 34 participants were spread across four "Part B" groups, which tested various combinations of margetuximab, chemotherapy, and other drugs, including a comparison group that received the standard drug trastuzumab with chemotherapy. The trial was measu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02795988 · results posted 16 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02795988) tested an experimental treatment called IMU-131 in people with a specific type of cancer. The trial ran in stages: a Phase 1b safety-focused stage (14 participants across three dose levels of IMU-131 combined with chemotherapy), a Phase 2 stage that compared IMU-131 plus chemotherapy against chemotherapy alone (19 participants in the combination group and 17 in the chemotherapy-only group), and a Phase 2 Extension stage testing two higher doses of IMU-131 on its own (7 participants per dose group). The trial was...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03615326 · results posted 17 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 738 participants in total. The global part of the trial included 350 people who received pembrolizumab (an immunotherapy medicine) added to standard chemotherapy, and 348 people who received standard chemotherapy alone. A separate smaller group based in Japan included 20 people in each of two similar treatment arms. The trial was measuring how long participants lived without their cancer growing (called progression-free survival), how long they lived overall (overall survival), how many had their tumours shrink or dis...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03894618 · results posted 14 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03894618) tested an investigational drug called SL-279252 in 50 people in total across 15 different dose groups. Participants were given the drug at doses ranging from very low (0.0001 mg per kilogram of body weight) up to much higher levels (24.0 mg per kilogram), across two different dosing schedules (referred to as S1 and S2). All 50 participants who started the trial completed it. The trial was primarily measuring how many participants experienced certain unwanted side effects — called "treatment-emergent adverse event...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05883345 · results posted 11 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 1,490 participants, split into two groups: 1,346 people who did not have gastric (stomach) growths, and 144 people who did. The trial was measuring whether certain blood test results — specifically a protein ratio called the pepsinogen I/II ratio, and a hormone called Gastrin-17 — were different between the two groups. Not everyone who started the study completed it: 979 people in the no-growth group and 122 in the growth group finished. The reported data shows that the pepsinogen I/II ratio (a measure whe...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04032704 · results posted 10 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04032704) was split into two parts — Part A and Part B — and tested a drug (referred to as "LV") at different doses across a range of cancer types, grouped into separate cohorts. In Part A, 49 people took part across six cohorts, all receiving a dose of 2.5 mg/kg. In Part B, 156 people took part across twelve cohorts, receiving either 1.25 mg/kg or 1.0 mg/kg. The main thing the trial was measuring was the proportion of participants whose tumours shrank by a meaningful amount — called the "objective response rate" (ORR) — b...
-
NCT03504397 · results posted 26 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03504397) enrolled 565 people in total — 283 in the group receiving zolbetuximab combined with a chemotherapy regimen called mFOLFOX6, and 282 in the group receiving a placebo combined with the same chemotherapy. The trial was measuring how long participants lived without their cancer getting worse (called progression-free survival), how long they survived overall, how their quality of life changed over time, and how many experienced a measurable shrinkage or disappearance of their tumour. The reported data shows that, fo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04499924 · results posted 22 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04499924) enrolled 17 people in total — 8 in a group receiving a lower dose of paclitaxel (60 mg/m²) and 9 in a group receiving a higher dose (80 mg/m²). The trial was testing a combination of four medicines — tucatinib, trastuzumab, ramucirumab, and paclitaxel — and was focused on finding a suitable paclitaxel dose. The main things being tracked were serious side-effect events during the first treatment cycle (called dose-limiting toxicities), any medical events that appeared or worsened during treatment (called treatment...
-
NCT04535414 · results posted 17 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04535414) enrolled people who carry a change in a gene called CDH1, which is linked to a hereditary risk of stomach cancer. Participants were randomly placed into one of two groups: 98 people followed the "Bethesda Protocol" (the investigational approach) and 97 followed the "Cambridge Method" (the standard comparison approach). Both groups also had a procedure called confocal endomicroscopy — a specialised camera technique used during a stomach examination. The trial was measuring how well each approach could detect early...
-
NCT04171141 · results posted 16 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04171141) tested an investigational drug called PF-07062119, either on its own at different dose levels or combined with one of two other drugs (PF-06801591 or bevacizumab). A total of 79 people took part across 16 different dose groups. The trial was an early-phase study, so its main focus was on closely monitoring participants for certain pre-defined serious medical events (called "dose-limiting toxicities," or DLTs — meaning significant harmful reactions that could signal a dose is too high) and tracking all medical eve...
-
NCT03980925 · results posted 13 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 37 participants, all of whom received a combination of nivolumab (an immunotherapy drug) and platinum-based chemotherapy. The trial had two phases: an induction phase (an initial, more intensive treatment period), in which all 37 participants started and completed, and a maintenance phase (an ongoing, follow-up treatment period), in which 24 participants started and completed. The main thing the trial was measuring was how many participants were still alive 12 months after starting treatment. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03150810 · results posted 20 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03150810) enrolled a total of 139 people across multiple groups. Participants were tested with two drugs given together — pamiparib and temozolomide (TMZ) — across a range of doses and dosing schedules. The trial had two main phases: a "dose escalation" phase (where researchers tested different dose levels and schedules to find an appropriate dose) and a "dose expansion" phase (where specific cancer types were studied further, including gastric cancer, ovarian cancer, small cell lung cancer, triple-negative breast cancer,...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05071053 · results posted 5 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05071053) enrolled 35 participants, all of whom received a combination of two drugs: tusamitamab ravtansine and ramucirumab. The trial was looking at two main things: whether certain serious side effects (called dose-limiting toxicities, or DLTs — meaning side effects severe enough to limit how much of the drug could be given) occurred in the first two cycles of treatment, and how many participants' tumours shrank or disappeared, known as the objective response rate (ORR). None of the 35 participants were recorded as havin...
-
NCT04508140 · results posted 29 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04508140) enrolled 18 people across two groups — 11 participants in Cohort A and 7 in Cohort B. The trial was testing a combination of two treatments (BO-112, given directly into liver tumours, and pembrolizumab, given through a drip) in people with cancer that had spread to the liver. The trial measured how many participants' tumours shrank or responded to treatment, how long participants went without their disease getting worse, and how many experienced serious side effects. The reported data shows that across both Coho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04711135 · results posted 27 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 11 adolescent participants in total — 4 with a type of tumour called a gastroenteropancreatic neuroendocrine tumour (GEP-NET) and 7 with tumours called pheochromocytoma or paraganglioma (PPGL). The trial was looking at a treatment called Lutathera, which delivers radiation directly to tumour cells. The study measured how much radiation was absorbed by key organs (the kidneys and bone marrow), and tracked any unwanted side effects or abnormal lab results that occurred during and after treatment. The reported data show...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04740164 · results posted 6 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 66 people in total — 33 in a group that used a device called the LMA Gastro (a specialised airway device placed in the throat) and 33 in a group that received standard care using a nasal cannula (a small tube that sits under the nose to deliver oxygen). The trial was measuring what happened to people's oxygen levels and airway management during a procedure called ERCP, which is a procedure that examines the digestive tract. Of those who started, 26 people in the LMA Gastro group and 30 in the standard care group compl...
-
NCT04852679 · results posted 1 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04852679) enrolled 43 participants, all of whom received a medicine called Lanreotide Autogel 120 mg. The trial had one main treatment period of 24 weeks, followed by a shorter independent injection period for a small subset of participants. The main thing the trial set out to measure was the "clinical benefit rate" — that is, the proportion of participants whose tumours either shrank, disappeared completely, or stayed stable (did not grow significantly) by the 24-week mark, as assessed by an independent review team lookin...
-
NCT04078152 · results posted 4 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04078152) enrolled 163 people across three groups. One hundred participants were in Cohort 1 (continuing treatment with a medicine called durvalumab), 25 were in Cohort 2 (restarting durvalumab after a break), and 38 were in Cohort 3 (not restarting durvalumab). The trial was looking at unwanted medical events (called adverse events) that occurred during the study, as well as how many people were still alive and, for those who restarted durvalumab, whether their cancer showed any measurable shrinkage. The reported data sh...
See all 112 reported results for Stomach Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, stomach cancer is receiving a substantial level of public research investment from the United States, and that investment has been rising year on year. This upward trend is an encouraging sign that the scientific community is placing growing importance on understanding and addressing this disease. For patients, rising public funding generally means more research acti...
See the full Stomach Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.